Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
2021
-
2022
Fluorescence of 5-Arylvinyl-5′-Methyl-2,2′-Bipyridyl Ligands and Their Zinc Complexes
Published 2009“…The photophysical properties of 5-arylvinyl-5′-methyl-2,2′-bipyridyls (AVMBs, <b>1</b>−<b>9</b>, <b>11</b>) and their zinc complexes were studied. …”
-
2023
Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist.
Published 2012“…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
-
2024
-
2025
-
2026
-
2027
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
2028
Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue.
Published 2017“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
-
2029
-
2030
-
2031
-
2032
-
2033
-
2034
-
2035
-
2036
-
2037
-
2038
-
2039
-
2040
Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers.
Published 2016“…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”